Deutsch English Français

Contact

EP2806736

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2806736

EP2806736 - METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING ATTENTION DEFICIT HYPERACTIVITY DISORDER [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 08.09.2017 Database last updated on 11.09.2024
Former	Examination is in progress Status updated on 23.12.2016
Most recent event Tooltip	08.09.2017	Application deemed to be withdrawn	published on 11.10.2017 [2017/41]
Applicant(s)	For all designated states Omthera Pharmaceuticals Inc. 1800 Concord Pike Wilmington, DE 19803 / US
	For all designated states Davidson, Michael H. 140 Belle Avenue Highland Park, Illinois 60035 / US
	For all designated states Wisler, Gerald L. 9713 Green Island Cove Windemere, Florida 34786 / US
	[2015/35]
Former [2014/49]	For all designated states Omthera Pharmaceuticals, Inc. PO Box 7237 90 Washington Valley Road Bedminster, New Jersey 07921 / US
	For all designated states Davidson, Michael H. 140 Belle Avenue Highland Park, Illinois 60035 / US
	For all designated states Wisler, Gerald L. 9713 Green Island Cove Windemere, Florida 34786 / US
Inventor(s)	01 / DAVIDSON, Michael H. 140 Belle Avenue Highland Park, Illinois 60035 / US
	02 / WISLER, Gerald L. 9713 Green Island Cove Windemere, Florida 34786 / US
	[2014/49]
Representative(s)	AstraZeneca Intellectual Property Eastbrook House Shaftesbury Road Cambridge CB2 8BF / GB
	[N/P]
Former [2014/49]	Roques, Sarah Elizabeth J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
Application number, filing date	12841851.4	19.10.2012
	WO2012US61131
Priority number, date	US201161549917P	21.10.2011 Original published format: US 201161549917 P
	[2014/49]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2013059669
	Date:	25.04.2013
	Language:	EN
	[2013/17]
	Type:	A1 Application with search report
	No.:	EP2806736
	Date:	03.12.2014
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 25.04.2013 takes the place of the publication of the European patent application.
	[2014/49]
Search report(s)	International search report - published on:	US	25.04.2013
	(Supplementary) European search report - dispatched on:	EP	10.09.2015
Classification	IPC:	A01N37/00	[2014/49]
	CPC:	A61K31/202 (EP,US); G01N33/92 (US); A23L33/12 (EP,US); A61K31/232 (EP,US); A61K45/06 (US); A61K9/006 (US); (+) A61P25/14 (EP); A61P25/18 (EP); A61P25/20 (EP); A61P25/22 (EP); C12Q1/26 (EP,US); C12Q1/6883 (US); C12Q2600/156 (US); G01N2800/305 (US); G01N2800/50 (US); Y10T436/143333 (EP,US) (-)
	C-Set:	A61K31/202, A61K2300/00 (EP,US); A61K31/232, A61K2300/00 (US,EP)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/49]
Title	German:	VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG ODER PRÄVENTION VON AUFMERKSAMKEITSDEFIZITSTÖRUNG	[2014/49]
	English:	METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING ATTENTION DEFICIT HYPERACTIVITY DISORDER	[2014/49]
	French:	MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT OU LA PRÉVENTION D'UN TROUBLE DE L'HYPERACTIVITÉ AVEC DÉFICIT DE L'ATTENTION	[2014/49]
Entry into regional phase	01.05.2014	National basic fee paid
	01.05.2014	Search fee paid
	01.05.2014	Designation fee(s) paid
	01.05.2014	Examination fee paid
Examination procedure	01.05.2014	Examination requested [2014/49]
	06.04.2016	Amendment by applicant (claims and/or description)
	22.12.2016	Despatch of a communication from the examining division (Time limit: M04)
	03.05.2017	Application deemed to be withdrawn, date of legal effect [2017/41]
	01.06.2017	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2017/41]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 22.12.2016
Fees paid	Renewal fee
	10.10.2014	Renewal fee patent year 03
	02.11.2015	Renewal fee patent year 04
	31.10.2016	Renewal fee patent year 05
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[Y]US2002040058 (KILIAAN AMANDA JOHANNE [NL], et al) [Y] 1-15 * the whole document *;
		[Y]WO2006127620 (MASSACHUSETTS INST TECHNOLOGY [US], et al) [Y] 1-15* the whole document *;
		[Y]WO2008147562 (CHILDRENS S MEDICAL CT CORP [US], et al) [Y] 1-15 * the whole document *;
		[XY]US2009074857 (DROR GAI BEN [IL], et al) [X] 4,5 * the whole document * * paragraphs [0054] - [0064] - [0 50]; claims 1-22 * [Y] 1-3,6-15;
		[Y]WO2011115476 (NUTRICIA NV [NL], et al) [Y] 1-15 * the whole document *;
		[X] - JAN PHILIPP SCHUCHARDT ET AL, "Significance of long-chain polyunsaturated fatty acids (PUFAs) for the development and behaviour of children", EUROPEAN JOURNAL OF PEDIATRICS, SPRINGER, BERLIN, DE, (20090812), vol. 169, no. 2, ISSN 1432-1076, pages 149 - 164, XP019781552 [X] 1-15 * the whole document * * abstract * * page 153, column right - page 158, column right; tables 1-4 * * page 159, column right - page 160, column right; figures 1-3 * * page 150, column right, paragraph second *
		[Y] - BURGESS J R ET AL, "LONG-CHAIN POLYUNSATURATED FATTY ACIDS IN CHILDREN WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER", THE AMERICAN JOURNAL OF CLINICAL NUTRITION, AMERICAN SOCIETY FOR NUTRITION, US, (20000101), vol. 71, no. 1, SUPPL, ISSN 0002-9165, pages 327S - 330S, XP008000462 [Y] 1-15 * the whole document * * abstract * * page 1053 - page 1060 *
		[Y] - LATTKA E ET AL, "Do FADS genotypes enhance our knowledge about fatty acid related phenotypes?", CLINICAL NUTRITION, CHURCHILL LIVINGSTONE, LONDON, GB, vol. 29, no. 3, doi:10.1016/J.CLNU.2009.11.005, ISSN 0261-5614, (20100601), pages 277 - 287, (20091130), XP027069482 [Y] 1-15 * the whole document * * abstract * * page 277 - page 284; figures 1,2; tables 1,2 * DOI: http://dx.doi.org/10.1016/j.clnu.2009.11.005
		[Y] - BROOKES ET AL, "Association of Fatty Acid Desaturase Genes with Attention-Deficit/Hyperactivity Disorder", BIOLOGICAL PSYCHIATRY, ELSEVIER SCIENCE, NEW YORK, NY; US, (20061101), vol. 60, no. 10, doi:10.1016/J.BIOPSYCH.2006.04.025, ISSN 0006-3223, pages 1053 - 1061, XP005842416 [Y] 1-15 * the whole document * * page 1053 - page 1060; tables 1-4 * DOI: http://dx.doi.org/10.1016/j.biopsych.2006.04.025
		[Y] - SYLVIE CHALON, "The role of fatty acids in the treatment of ADHD", NEUROPHARMACOLOGY, (20091201), vol. 57, no. 7-8, doi:10.1016/j.neuropharm.2009.08.012, ISSN 0028-3908, pages 636 - 639, XP055209764 [Y] 1-15 * the whole document * * abstract * * page 327S - page 329S; table 1 * DOI: http://dx.doi.org/10.1016/j.neuropharm.2009.08.012
		[Y] - FOR THE INTERNATIONAL SOCIETY FOR THE STUDY OF FATTY ACIDS AND LIPIDS ET AL, "alpha-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans", PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, CHURCHILL LIVINGSTONE, EDINBURGH, vol. 80, no. 2-3, doi:10.1016/J.PLEFA.2009.01.004, ISSN 0952-3278, (20090201), pages 85 - 91, (20090309), XP025974211 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/j.plefa.2009.01.004
		[Y] - Stacey Ageranioti Bélanger ET AL, "Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: A randomized, double-blind, placebo-controlled study", Paediatrics & child health, Canada, (20090201), pages 89 - 98, URL: http://www.ncbi.nlm.nih.gov/pubmed/19436468, (20150827), XP055209919 [Y] 1-15 * the whole document *
	International search	[Y]US5855949 (MCLEAN LINSEY [US]);
		[Y]WO2005086619 (MCLEAN HOSPITAL CORP [US], et al);
		[Y]WO2006127627 (MASSACHUSETTS INST TECHNOLOGY [US], et al);
		[Y]WO2007075841 (CENESTRA LLC [US], et al);
		[X] - SCHUCHARDT ET AL., "Significance of long-chain polyunsaturated fatty acids (PUFAs) for the development and behaviour of children.", EUROPEAN JOURNAL OF PEDIATRICS, (20090812), vol. 169, no. 2, pages 149 - 164, XP019781552
		[Y] - STEVENS ET AL., "Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder.", AMERICAN JOURNAL OF CLINICAL NUTRITION, (19950525), vol. 62, pages 761 - 768, XP003023958
		[Y] - BROOKES ET AL., "Association of Fatty Acid Desaturase Genes with Attention-Deficit/Hyperactivity Disorder.", BIOLOGICAL PSYCHIATRY, (20060413), vol. 60, pages 1053 - 1061, XP005842416 DOI: http://dx.doi.org/10.1016/j.biopsych.2006.04.025

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p